Australia markets closed

NaturalShrimp Incorporated (SHMP)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.3500-0.0211 (-5.69%)
At close: 03:59PM EST
Full screen
Loading interactive chart…
  • GlobeNewswire

    NaturalShrimp Electrocoagulation Technology Shown to Reduce Nitrites in Recirculating Aquaculture Systems

    DALLAS, TX, Jan. 06, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- NaturalShrimp, Inc. (OTCQB: SHMP), a Biotechnology Aquaculture Company that has developed and patented the first shrimp-focused, commercially operational RAS (Recirculating Aquaculture System), today announced a new discovery from the NaturalShrimp technical team. The team demonstrated that its patented electrocoagulation (EC) technology can reduce nitrites without the need for a biofilter in a recirculating aquaculture system (RA

  • GlobeNewswire

    NaturalShrimp to Expand Production at Current Facilities and with Planned New Facilities in Florida and Nevada

    DALLAS, TX, Jan. 03, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – NaturalShrimp, Inc. (OTCQB: SHMP), a Biotechnology Aquaculture Company that has developed and patented the first shrimp-focused, commercially operational RAS (Recirculating Aquaculture System), today announced it will expand production at its existing Texas and Iowa shrimp production facilities, and with new planned facilities in Florida and Nevada. NaturalShrimp will begin construction of a new shrimp production building on its 37

  • GlobeNewswire

    NaturalShrimp Announces Second Phase Trial for Freshwater Salmon

    DALLAS, TX, Dec. 30, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- NaturalShrimp, Inc. (OTCQB: SHMP), a Biotechnology Aquaculture Company that has developed and patented the first shrimp-focused, commercially operational RAS (Recirculating Aquaculture System), today announced the funding of a second freshwater salmon trial at the Marineholmen RASLab, in Bergen, Norway. In September 2021, the Company announced initial trial results of its short-term validation study at the Marineholmen RASLab to e